Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents. 

A carotid artery atherosclerotic plaque blockage at the bifurcation seen here can cause strokes. The stenting these lesions is a less invasive way of treating than open vessel surgery. The SVS has issued guidelines to help guide credentialing for the carotid stent procedure. Image from Vital Images.
News | Stroke
Society for Vascular Surgery Outlines What is Needed for Trans-Carotid Artery Revascularization Training and Credentialing

July 9, 2020 — The Society for Vascular Surgery (SVS) has released a clinical competence statement on training and ...

Home July 09, 2020
Home
he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   
News | Peripheral Artery Disease (PAD)
Excellent 3-year Results in MIMICS-2 Study of the BioMimics 3D Vascular Stent 

June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent ...

Home June 16, 2020
Home
Coronary and Peripheral Stent Market Expected to Double Through 2025
News | Stents
Coronary and Peripheral Stent Market Expected to Double Through 2025

May 28, 2020 — The rising incidence of cardiovascular disease has prompted people to seek timely treatment to improve ...

Home May 28, 2020
Home
Christopher Baker, M.D., and his team perpare to perform their first robotically navigated carotid artery stenting procedure at Hoag Memorial Hospital Presbyterian. The Corindus Corpath robotic system can be seen over the patient on the table.
News | Robotic Systems
Hoag Performs First Robotic Carotid Artery Stenting on West Coast

May 28, 2020 — Hoag Memorial Hospital Presbyterian recently became the first hospital on the West Coast to perform an ...

Home May 28, 2020
Home
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020
News | Stents
TWILIGHT Trial Substudy Examines Bioabsorbable Polymer vs. Durable Polymer Drug-Eluting Stents in High-Risk PCI

May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) ...

Home May 17, 2020
Home
Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.
News | Stents
Biotronik's Orsiro Stent Continues Excellent Results After Three Years

February 24, 2020 — Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the ...

Home February 24, 2020
Home
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Cardiovascular Business
DAIC Named a Finalist in the 66th Annual Jesse H. Neal Awards

February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced the ...

Home February 19, 2020
Home
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.
Feature | Stents | Saloni Walimbe
Innovations in Cardiovascular Disease Treatment and the Rising Demand for Stents 

Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high ...

Home February 11, 2020
Home
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.
News | Cath Lab | Dave Fornell, Editor
EXCEL Trial Authors Say European Surgery Society Claims of Bad Science Are Groundless

January 2, 2020 — In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdre ...

Home January 02, 2020
Home
The American Heart Association, AHA, 2019 meeting late breaking trials and key studies on cardiovascular science.
Feature | AHA | Dave Fornell, Editor
American Heart Association 2019 Late-breaking Trials

November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at the ...

Home November 19, 2019
Home
The repuncturable Supera vascular mimetic peripheral stent system from Abbott Vascular was shown to manage bulky, heavily calcified CFA disease due to its extreme crush resistance in the VMI-CFA study. #VIVA #VIVA19 #VIVA2019
News | Stents Carotid
Supera Safe to use for Femoral Stenting Versus Surgery in VMI-CFA Trial

November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard treatment ...

Home November 11, 2019
Home
Bioresorbable stent Abbott Absorb stent
News
One-Year Results of the DISAPEAR Registry Positive for Absorb Stent

November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with ...

Home November 08, 2019
Home
News | Stents Bioresorbable
Bioresorbable Stent Shows Good 5-Year Outcomes in ABSORB BTK Trial

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due ...

Home November 07, 2019
Home
The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019
Feature | Stents Peripheral | Dave Fornell, Editor
No Increased Long-Term Mortality for the Paclitaxel-Coated Zilver PTX Stent

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

Home November 06, 2019
Home
Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD)
Positive Data for the Ranger Drug-coated Balloon and Eluvia Vascular Stent

November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting ...

Home November 06, 2019
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now